Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RC118
- Development stage
- Phase 2
- Lead developer
- RemeGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
RC118 is an investigational antibody-drug conjugate (ADC) developed by RemeGen for the treatment of solid tumors that express Claudin 18.2, including gastric cancer (and gastroesophageal junction cancer) and pancreatic cancer. The drug consists of a recombinant humanized IgG1 monoclonal antibody targeting Claudin 18.2, conjugated to the cytotoxic agent monomethyl auristatin E (MMAE). By binding to Claudin 18.2 on tumor cells, RC118 delivers MMAE directly into the malignant cells, leading to cell death while minimizing off-target toxicity. It has demonstrated favorable safety and tolerability in phase I clinical trials in China and Australia and has been granted orphan drug designation by the US FDA for both gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer[2][3][4][5].
- Other names
- Recombinant humanized anti-MSLN monoclonal antibody-monomethyl auristatin E conjugate
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on RC118.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RC118.